Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.

摘要: Lymphomas express a tumor-specific antigen which can be targeted by cancer vaccination. We evaluated the ability of new idiotype protein vaccine formulation to eradicate residual t(14;18)+ lymphoma cells in 20 patients homogeneous, chemotherapy-induced first clinical complete remission. All 11 with detectable translocations their primary tumors had from malignant clone blood PCR both at diagnosis and after chemotherapy, despite being However, 8 converted lacking vaccination sustained molecular remissions. Tumor-specific cytotoxic CD8+ CD4+ T were uniformly found (19 patients), whereas antibodies detected, but apparently not required for Vaccination was thus associated clearance tumor long-term disease-free survival. The demonstration remissions, analysis lymphocytes against autologous targets, addition granulocyte-monocyte colony-stimulating factor provide principles relevant design future trials other vaccines administered minimal disease setting.